drugset

drugset / Trial / NCT02265627

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

NCT02265627 ↗

Phase 1 Completed 32 enrolled Boehringer Ingelheim

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To investigate the pharmacokinetics of a single dose of BIIL 284 BS in patients with hepatic impairment in comparison to healthy subjects

Timeline

Start: 2000-03
Primary completion: 2000-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMELUBANT	Small molecule	—	—

Indications